AI integration in drug discovery and biotechnology

The pharmaceutical and biotechnology sectors are increasingly integrating generative artificial intelligence to accelerate drug discovery and molecular design.

Pfizer has entered a licensing agreement with Chai Discovery to utilize its generative-AI platform, including the Chai-3 model and a system customized with Pfizer’s proprietary data. This partnership aims to design antibodies and biomolecules, potentially reducing the time and billions of dollars typically required for drug development. However, experts note that AI-generated leads must still undergo traditional laboratory testing, animal studies, human trials, and regulatory approval, emphasizing that AI is a research tool rather than a replacement for scientific judgment.

Other industry developments include the British startup Kiin Bio securing €1.9 million in pre-seed funding to launch its KiinOS Virtual Scientist Platform, which seeks to unify fragmented discovery tools. Kiin Bio has also partnered with Collaborative Drug Discovery (CDD) to integrate its platform with the CDD Vault data management system. Meanwhile, Chai Discovery, a startup supported by OpenAI, has signed multiple strategic agreements to advance molecular design tools that aim for precision in creating effective drugs with reduced toxicity risks.

A report from TPC Marketing Research indicates the industry is transitioning from using AI for research support toward the practical commercialization of actual drug candidates. The report identifies three primary strategic actors: pharmaceutical companies implementing AI in R&D, specialized AI ventures, and Big Tech companies providing essential computational infrastructure like cloud services and GPUs.